Healthy Volunteer, Psychedelic Experiences, Virtual Reality
Conditions
Brief summary
The purpose of this study is to evaluate a novel VRP.
Detailed description
The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.
Interventions
DEVICEMeta Quest 3
Meta Quest 3 is a virtual reality headset device
Sponsors
Yale University
Study design
Observational model
CASE_CROSSOVER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to provide informed consent * No history or current DSM-V diagnosis
Exclusion criteria
* Unstable medical conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics. | Day 0 through Day 30 | Subject experience will be assessed using the Altered States of Consciousness Rating Scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain. | Day 0 through Day 30 | The number of adverse events will be assessed through qualitative interviews following VRP viewing. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAnahita Bassir Nia, MD
Yale University
Outcome results
None listed